BFG
HZNP

Bleakley Financial Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Bleakley Financial Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,164
Closed -$482K – 993
2023
Q3 		$482K Sell
4,164
-512
-11% -$55K 0.02% 547
2023
Q2 		$481K Buy
4,676
+1,207
+35% +$127K 0.02% 596
2023
Q1 		$379K Buy
3,469
+30
+0.9% +$3.32K 0.01% 644
2022
Q4 		$391K Buy
+3,439
New +$286K 0.01% 613

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Bleakley Financial Group's HZNP Position: Q4 2023 in Review

Bleakley Financial Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,164 shares — an estimated $482K sold.

Bleakley Financial Group first reported a position in HZNP in Q4 2022 and held it in 4 quarters. The position peaked at $482K in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Bleakley Financial Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Bleakley Financial Group sold 4,164 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $482K.
  • Bleakley Financial Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 4 quarters.
  • Bleakley Financial Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $482K in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Bleakley Financial Group's 13F filing for Q4 2023, filed 25 Jan 2024.